Modality
Vaccine
MOA
JAK1i
Target
GLP-1R
Pathway
T-cell
Prostate Ca
Development Pipeline
Preclinical
~Oct 2010
→ ~Jan 2012
Phase 1
~Apr 2012
→ ~Jul 2013
Phase 2
~Oct 2013
→ ~Jan 2015
Phase 3
~Apr 2015
→ ~Jul 2016
NDA/BLA
~Oct 2016
→ ~Jan 2018
Approved
Apr 2018
→ Jan 2031
ApprovedCurrent
NCT04299841
1,786 pts·Prostate Ca
2020-11→2029-08·Not yet recruiting
NCT05549861
2,718 pts·Prostate Ca
2025-09→2026-12·Terminated
NCT04936064
1,818 pts·Prostate Ca
2018-04→2031-01·Not yet recruiting
6,322 total pts1 indication
CompletedCurrentUpcoming
Catalysts (3)
2026-12-138mo awayPh3 Readout· Prostate Ca
2029-08-103.4y awayPh3 Readout· Prostate Ca
2031-01-014.8y awayPh3 Readout· Prostate Ca
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
Approved
Not yet…
Approved
Not yet…
Approved
Termina…
Catalysts
Ph3 Readout
2026-12-13 · 8mo away
Prostate Ca
Ph3 Readout
2029-08-10 · 3.4y away
Prostate Ca
Ph3 Readout
2031-01-01 · 4.8y away
Prostate Ca
TerminatedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04299841 | Approved | Prostate Ca | Not yet recr... | 1786 | DAS28 |
| NCT05549861 | Approved | Prostate Ca | Terminated | 2718 | SRI-4 |
| NCT04936064 | Approved | Prostate Ca | Not yet recr... | 1818 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R |